Aggressive giant cell granuloma of the jaws treated with interferon alpha: a report of two cases

• Published in: Irish journal of medical science Vol. 182; no. 2; pp. 163 - 170
• Main Authors: O’Connell, J. E., Kearns, G. J.
• Format: Journal Article
• Language: English
• Published: London Springer-Verlag 01.06.2013
• Subjects: Adult; Angiogenesis Inhibitors - therapeutic use; Child; Combined Modality Therapy; Family Medicine; Female; General Practice; Granuloma, Giant Cell - drug therapy; Granuloma, Giant Cell - surgery; Humans; Interferon-alpha - therapeutic use; Internal Medicine; Jaw Neoplasms - drug therapy; Jaw Neoplasms - surgery; Medicine; Medicine & Public Health; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - surgery; Recombinant Proteins - therapeutic use; Review Article; Aggressive giant cell granuloma; Giant cell tumour of the jaws; Interferon; Interferon alpha
• ISSN: 0021-1265; 1863-4362
• DOI: 10.1007/s11845-012-0858-x

Background Giant cell granulomas (GCGs) are benign tumours of the jaws of unknown aetiology. Aggressive lesions are difficult to manage and demonstrate a tendency to recur after surgical curettage. In the early 1980s, interferon alpha-2a was found to inhibit angiogenesis through a series of laboratory experiments and was subsequently used to treat a child with pulmonary haemangiomatosis. It has been hypothesised that GCGs are proliferative vascular lesions and would, therefor, be expected to respond to antiangiogenic therapy. The purpose of this study is to report a treatment protocol consisting of enucleation, followed by subcutaneous interferon alpha. Methods Patients with a biopsy-confirmed giant cell lesion satisfying criteria for “aggressive” giant cell tumours were included. All lesions were enucleated, and the patients commenced interferon alpha-2a (3,000,000 units/m 2 ) 48–72 h post-operatively. Results Two patients satisfied the criteria for aggressive giant cell lesions. All tumours were enucleated. There were no post-operative complications, and all patients tolerated the interferon therapy well. To date, there has been no evidence of tumour recurrence. The follow-up periods were 144 and 81 months, respectively. Conclusion Antiangiogenic therapy, in combination with curettage, has proven to be a useful strategy for the management of these tumours. The use of interferon alpha-2a, following enucleation of these lesions, resulted in complete remission of all lesions, and decreased operative morbidity compared with conventional treatment.